Table 1.
Other onconeural antibodies seen in limbic encephalitis
| Antibody | Associated conditions |
|---|---|
| Ma1/Ma2 | Breast, Colon and Testicular (Ma1);Testicular Germ Cell Tumor (Ma2) |
| Cv2/Collapsing Response Mediator Protein‐5 | Thymoma and SCLC |
| ANNA‐1 (anti‐Hu) | SCLC |
| ANNA‐2 | SCLC, Breast Adenocarcinoma |
| ANNA‐3 | Aerodigestive Carcinomas |
| PCA‐1 | Adenocarcinoma of the Breast and Mullerian Ducts |
| PCA‐2 | SCLC |
| PCA‐Tr/CRMP‐5 IgG | Hodgkin Lymphoma, SCLC, Thymoma |
| Amphiphysin IgG | SCLC and Breast Adenocarcinoma |
| GAD65 | Tumors of Kidneys, Breast, Colon, and Thymus |
| GABA‐B | SCLC and Other Neuroendocrine Neoplasia |
| AMPAR | Lung, Breast, or Thymus Tumors |
| mGLuR5 | Hodgkin Lymphoma |
| VGKC (or anti‐LG1) | SCLC, Thymoma, Adenocarcinoma of the Breast or Prostate |
| NMDA | Ovarian Teratoma |
ANNA, Antineuronal antibody; PCA, Purkinje cell cytoplasmic antibody; GAD65, 65 kDa isoform of glutamic acid decarboxylase; GABA, Gamma amino butyric acid; AMPAR, Alpha‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor; mGluR5, Metabotropic glutamate receptor 5; VGKC, Voltage‐gated potassium channel; LG1, Leucine‐rich glioma inactivated 1; NMDA, N‐methyl‐D‐aspartate; SCLC, Small‐cell lung carcinoma.